Population tailored modification of tuberculosis specific interferon-gamma release assay
- PMID: 26632326
- PMCID: PMC4747975
- DOI: 10.1016/j.jinf.2015.10.012
Population tailored modification of tuberculosis specific interferon-gamma release assay
Abstract
Objectives: Blood-based Interferon-Gamma Release Assays (IGRA) identify Mycobacterium tuberculosis (MTB) sensitisation with increased specificity, but sensitivity remains impaired in human immunodeficiency virus (HIV) infected persons. The QuantiFERON-TB Gold In-Tube test contains peptide 38-55 of Rv2654c, based on data indicating differential recognition between tuberculosis patients and BCG vaccinated controls in Europe. We aimed to fine map the T cell response to Rv2654c with the view of improving sensitivity.
Methods: Interferon-gamma ELISpot assay was used in HIV uninfected persons with latent and active tuberculosis to map peptide epitopes of Rv2654c. A modified IGRA was tested in two further groups of 55 HIV uninfected and 44 HIV infected persons, recruited in South Africa.
Results: The most prominently recognised peptide was between amino acids 51-65. Using p51-65 to boost the QuantiFERON-TB Gold In-Tube assay, the quantitative performance of the modified IGRA increased from 1.83 IU/ml (IQR 0.30-7.35) to 2.83 (IQR 0.28-12.2; p = 0.002) in the HIV uninfected group. In the HIV infected cohort the percentage of positive responders increased from 57% to 64% but only after 3 months of ART (p = ns).
Conclusions: Our data shows the potential to population tailor detection of MTB sensitization using specific synthetic peptides and interferon-gamma release in vitro.
Keywords: HIV; Interferon-Gamma Release Assays (IGRA); Peptide epitope; QuantiFERON assay; Rv2654c; Tuberculosis.
Copyright © 2015 The Authors. Published by Elsevier Ltd.. All rights reserved.
Figures



References
-
- WHO . World Health Organization; Geneva: 2014. Global tuberculosis report 2014.http://www.who.int/tb/publications/global_report/en/
-
- Kaufmann S.H. Future vaccination strategies against tuberculosis: thinking outside the box. Immunity. 2010;33:567–577. - PubMed
-
- Andersen P., Doherty T.M. The success and failure of BCG—implications for a novel tuberculosis vaccine. Nat Rev Microbiol. 2005;3:656–662. - PubMed
-
- Farhat M., Greenaway C., Pai M., Menzies D. False-positive tuberculin skin tests: what is the absolute effect of BCG and non-tuberculous mycobacteria? Int J Tuberc Lung D. 2006;10:1192–1204. PMCID. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Miscellaneous